10x Genomics/$TXG
1D1W1MYTD1Y5YMAX
Capital at risk
About 10x Genomics
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
- Ticker
- $TXG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,178
- Headquarters
- Pleasanton, United States
- Website
- www.10xgenomics.com
10x Genomics Metrics
BasicAdvanced
$9.7B
-
-$0.59
2.04
-
Price and volume
Market cap
$9.7B
Beta
2.04
52-week high
$75.61
52-week low
$11.16
Average daily volume
3M
Financial strength
Current ratio
5.693
Quick ratio
5.085
Long term debt to equity
0.081
Total debt to equity
0.095
Profitability
EBITDA (TTM)
-41.201
Gross margin (TTM)
70.11%
Net profit margin (TTM)
-12.18%
Operating margin (TTM)
-13.16%
Effective tax rate (TTM)
-0.31%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-5.05%
Return on equity (TTM)
-9.40%
Valuation
Price to revenue (TTM)
15.397
Price to book
11.74
Price to tangible book (TTM)
12.79
Price to free cash flow (TTM)
78.217
Free cash flow yield (TTM)
1.28%
Free cash flow per share (TTM)
0.951
Growth
Revenue change (TTM)
-4.28%
Earnings per share change (TTM)
-14.94%
3-year revenue growth (CAGR)
2.77%
3-year earnings per share growth (CAGR)
-26.70%
What the Analysts think about 10x Genomics
Analyst ratings (Buy, Hold, Sell) for 10x Genomics stock.
Analyst projections of the future price of 10x Genomics stock.
Bulls say / Bears say
Atera could become a significant growth catalyst: management cited strong early customer response and order flow, with shipments expected to begin in the second half of 2026. (SEC)
Management raised 2026 revenue guidance to $610 million–$630 million, and Q2 gross margin improved to 74% from 72% year over year, indicating better operating execution and manufacturing economics. (SEC)
The Proteintech Genomics acquisition expands 10x Genomics’ multiomics capabilities, while collaborations with Cleveland Clinic and Lausanne University Hospital support its strategy to extend single-cell and spatial technologies into cancer diagnostics. (SEC)
Underlying growth remains modest: excluding litigation-related revenue, 10x Genomics reported only 3% year-over-year growth in Q2 2026 and guided to just 2%–5% growth for full-year 2026. (SEC)
Profitability remains a concern: Q2 2026 produced a $19.6 million operating loss and a $17.9 million net loss, while the company continues to carry a sizable accumulated deficit. (SEC)
Instrument and China demand were weak in Q2 2026: total instrument revenue fell to $7.7 million from $14.5 million year over year, while China revenue declined to $15.0 million from $23.2 million. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
10x Genomics Financial Performance
Revenues and expenses
10x Genomics Earnings Performance
Company profitability
Upcoming events
No upcoming events
10x Genomics News
AllArticlesVideos
Funds containing 10x Genomics
AllUSDEURGBP
Fund name | Fund size | $TXG weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.86% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.86% |
iShares Healthcare Innovation£DRDR | £1B | 0.86% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.55% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.55% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.